Somatuline Autogel 60 mg & 90 mg: Treatment of acromegaly when secretion of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy.
Treatment of the clinical syndrome associated with acromegaly.
Treatment of the clinical symptoms of neuroendocrine (particularly carcinoid) tumours.
Somatuline Autogel 120 mg: Treatment of acromegaly when secretion of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy.
Treatment of the clinical syndrome associated with acromegaly.
Treatment of the clinical symptoms of neuroendocrine (particularly carcinoid) tumours.
Treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.